Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Rating of “Hold” by Analysts

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been given a consensus recommendation of “Hold” by the five research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $4.50.

A number of equities analysts have recently commented on HRTX shares. Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Wednesday, October 8th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HRTX. B. Riley Wealth Advisors Inc. acquired a new position in shares of Heron Therapeutics during the second quarter worth approximately $26,000. R Squared Ltd bought a new position in Heron Therapeutics during the second quarter worth $26,000. PKS Advisory Services LLC bought a new position in Heron Therapeutics during the third quarter worth $25,000. Russell Investments Group Ltd. acquired a new position in Heron Therapeutics during the 2nd quarter valued at $43,000. Finally, Jones Financial Companies Lllp boosted its holdings in Heron Therapeutics by 5,541.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 23,661 shares during the period. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Price Performance

NASDAQ HRTX opened at $1.28 on Wednesday. Heron Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $2.68. The stock’s 50-day moving average is $1.21 and its two-hundred day moving average is $1.49. The firm has a market cap of $234.70 million, a P/E ratio of -14.22 and a beta of 1.34. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $38.21 million during the quarter, compared to analyst estimates of $39.03 million. On average, analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.